WebApr 4, 2024 · INTRODUCTION. KEYNOTE-042 is a randomized phase III study that showed significantly longer overall survival (OS) with pembrolizumab monotherapy versus platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) tumor … WebMar 7, 2024 · All parties involved in speaker programs including companies, speakers, and attendees will likely be subject to increased scrutiny going forward. The updated PhRMA …
ESMO 2024 Congress OncologyPRO
WebNovartis has faced myriad allegations of unethical or illegal behavior over the years. Last week, it agreed to pay $347 million to end probes into its overseas sales conduct under … WebSep 20, 2024 · Note that the revised PhRMA Code limits application of the enhanced standards on attendance to speaker programs where a meal is provided, suggesting the concern is the potential “inducement” provided in the form of a meal. Speaker Selection and Compensation. The revised PhRMA Code reaffirms that, when HCPs are speaking on … little debbie snack cakes nutrition facts
Ribociclib plus goserelin with hormonal therapy versus
WebApr 4, 2024 · INTRODUCTION. In the phase 3 KEYNOTE-189 study, pembrolizumab (an anti–programmed cell death protein-1 monoclonal antibody) plus pemetrexed and carboplatin/cisplatin significantly prolonged overall survival (OS; hazard ratio [HR], 0.49; 95% CI, 0.38 to 0.64; P < .001) and progression-free survival (PFS; 0.52; 0.43 to 0.64; P < .001) … WebThe Situation: The Department of Health and Human Services, Office of Inspector General ("OIG") issued a special fraud alert identifying what it termed "inherent fraud and abuse risks" associated with speaker programs—educational presentations conducted by health care providers ("HCPs") and compensated by the manufacturer—that pharmaceutical and … WebNovartis has represented that: (a) Third Party Personnel are employed by entities other than Novartis; (b) Novartis does not control the Third Party Personnel; and (c) it would be commercially impracticable to compel the compliance of Third Party Personnel with the requirements set forth in this CIA. Novartis agrees to promote compliance by Third little debbie snacks reviews